👤 Authors: Leo Westbury, Elizabeth M Curtis, Ewa Balkowiec-Iskra, Antonio Cherubini, Mario Miguel Coelho da Silva Rosa, Paolo Foggi, Yury Kiselev, Andrea Laslop, Sif Ormarsdóttir, Maria Concepcion Prieto Yerro, Carla Torre, Katarina Vucic, Majed Alokail, Ali Al-Samil, Gulistan Bahat, Mario Barbagallo, Jürgen M Bauer, Charlotte Beaudart, Angie Botto-van Bemden, Olivier Bruyère, Nansa Burlet, Etienne Cavalier, Alfonso J Cruz-Jentoft, Patrizia D'Amelio, Sandra De Breucker, Gustavo Duque, Roger A Fielding, Nicholas Fuggle, Andrea Gasparik, Mickaël Hiligsmann, Olivier Lamy, Stefania Maggi, Ali Mobasheri, Graziano Onder, Mirko Petrovic, Regis Radermecker, René Rizzoli, Shaun Sabico, Cornel Sieber, Nathalie van der Velde, Nicola Veronese, Marjolein Visser, Bruno Sepodes, Nicholas C Harvey, Jean-Yves Reginster
Development of treatments for sarcopenia: new challenges, opportunities and perspectives.
Sarcopenia is characterized by loss of muscle mass, strength and function, and is associated with decline in physical function, falls, fractures and premature mortality. Despite increasing recognition of its clinical and societal burden, progress in translating advances in sarcopenia research into approved pharmacological therapies has remained limited.
Potential barriers include heterogeneity in trial design regarding eligibility criteria, follow-up duration and outcomes, as well as limited regulatory harmonization. Given advances in sarcopenia research, the continued absence of approved treatments and the need to integrate perspectives that have emerged since the 2020 ESCEO recommendations for the conduct of sarcopenia clinical trials, this Perspective provides up-to-date expert perspectives on the development of treatments for sarcopenia, informed by discussions held by a working group convened by the World Health Organization Collaborating Centre for Epidemiology of Musculoskeletal Conditions and Ageing.
Developments in the definition of sarcopenia, the regulatory landscape and therapeutic approaches are presented, together with considerations for the design of pharmacological trials, including target populations, the selection and assessment of trial outcomes (including digital health measures and patient-reported outcome measures), trial duration, use of biomarkers and patient expectations of treatments.
